Research LetterDecreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease
Abbreviations used in this paper
Cited by (0)
Coronavirus Risk Associations and Longitudinal Evaluation-Inflammatory Bowel Disease (CORALE-IBD) Study Group: Keren Appel, Andrea Banty, Edward Feldman, Christina Ha, Rashmi Kumar, Susie Lee, Shervin Rabizadeh, Theodore Stein, Gaurav Syal, Stephan Targan, Eric Vasiliauskas, David Ziring, Philip Debbas, Melissa Hampton, Emebet Mengesha (Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California), James L. Stewart, Edwin C. Frias (Applied Research and Technology, Abbott Diagnostics, Abbott Park, Illinois), Susan Cheng, Joseph Ebinger (Smidt Heart Institute, Department of Medicine, Cedars-Sinai, Los Angeles, California), Jane C. Figueiredo (Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai, Los Angeles, California), Brigid Boland (University of California, San Diego, California), Aline Charabaty (Sibley Memorial Hospital, Johns Hopkins, Washington, District of Columbia), Michael Chiorean (Swedish Hospital, Seattle, Washington), Erica Cohen (Capital Digestive Care, Chevy Chase, Maryland), Ann Flynn, John Valentine (University of Utah, Salt Lake City, Utah), David Fudman (UT Southwestern, Dallas, Texas), Arash Horizon (Center for Rheumatology, Los Angeles, California), Jason Hou (Baylor College of Medicine, Houston, Texas), Caroline Hwang (Hoag Hospital, Newport Beach, California), Mark Lazarev (Johns Hopkins Hospital, Baltimore, Maryland), Donald Lum, Rebecca Fausel, Swapna Reddy (The Oregon Clinic, Portland, Oregon), Mark Mattar (Medstar-Georgetown, Washington, District of Columbia), Mark Metwally, Arthur Ostrov (Saratoga-Schenectady Gastroenterology, Saratoga Springs, New York), Nimisha Parekh (University of California, Irvine, California), Laura Raffals (The Mayo Clinic, Rochester, Minnesota), Sarah Sheibani (Keck Medicine of University of Southern California, Los Angeles, California), Corey Siegel (Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire), Douglas Wolf (Atlanta Gastroenterology Associates, Atlanta, Georgia), Ziad Younes (Gastro One, Germantown, Tennessee), Ryan McConnell (Sutter Health, Sacramento, California), Bradley Morganstern (Stony Brook University Hospital, Stony Brook, New York), Sarah Glover (University of Mississippi Medical Center, Jackson, Mississippi), and Adam Ehrlich (Temple University, Philadelphia, Pennylvania).
Conflicts of interest These authors disclose the following: Gil Y. Melmed has consulted for AbbVie, Boehringer-Ingelheim, Janssen, Pfizer, Samsung Bioepis, and Takeda, and has received research funding from Pfizer for an unrelated investigator-initiated study. Jonathan Braun has received research funding from Janssen. John Prostko, James L. Stewart, and Edwin C. Frias work for Abbott Diagnostics, a company that performed the serological assays on the biospecimens that were collected for this study. Dermot P. B. McGovern: Pfizer and Takeda. Michael Chiorean: Abbvie, Janssen, Pfizer, and Takeda. Erica Cohen: Abbvie and Pfizer. David Fudman: Pfizer. Caroline Hwang: Abbvie, Janssen, and Pfizer. Donald Lum: Abbvie, Janssen, and Takeda. Ryan McConnell: Abbvie and Pfizer. Nimisha Parekh: Pfizer. Douglas Wolf: Abbvie, Janssen, Pfizer, and Takeda. Bradley Morganstern: Abbvie, Janssen, Pfizer, and Takeda. Sarah Glover: Abbvie, Janssen, and Takeda. Christina Ha: Abbvie, Janssen, and Pfizer. Gaurav Syal: research funding for unrelated investigator study from Pfizer. Corey Siegel: Abbvie, Jannsen, and Pfizer. Adam Ehrlich: Pfizer. Kimia Sobhani: Abbott Diagnostics. The remaining authors disclose no conflicts.
Funding This study was supported by the The Leona M. and Harry B. Helmsley Charitable Trust, the Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, and the National Institute of Diabetes and Digestive and Kidney Disease Grants P01DK046763 and U01DK062413. This study has been additionally supported in part by the Cedars-Sinai Precision Health Initiative and the Erika J. Glazer Family Foundation.